Emergent Biosolutions, Inc. (EBS) is a publicly traded Healthcare sector company. As of July 22, 2026, EBS trades at $7.58 with a market cap of $394.71M and a P/E ratio of -54.39. EBS moved -0.92% today. Year to date, EBS is -38.67%; over the trailing twelve months it is +5.87%. Its 52-week range spans $4.02 to $14.06. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces EBS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest EBS news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $7.58 |
| Market Cap | $394.71M |
| P/E Ratio | -54.39 |
| EPS | $-0.14 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.06 |
| 52-Week Low | $4.02 |
| Volume | 304.02K |
| Avg Volume | 0 |
| Revenue (TTM) | $676.80M |
| Net Income | $-8.60M |
| Gross Margin | 54.24% |
1 analysts cover EBS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.